CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 111 enrolled
Drug / intervention
Hydrocortisone +2 moredrug
Likely dose
Hydrocortisone 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00674570
NCT00674570Phase 4Completed
CompareCT.gov

Effects of Hydrocortisone and D-Cycloserine on Fear Extinction in Veterans With Posttraumatic Stress Disorder

VA Office of Research and Development·interventional·Posted May 8, 2008·Updated May 30, 2019

In Brief

A Phase 4 clinical trial evaluating Hydrocortisone, D-Cycloserine, and 1 other intervention for Stress Disorders, Posttraumatic. Completed, enrolled 111 participants across 1 site.

Detailed Summary

This is a research study examining the use of two medications, Hydrocortisone and D-Cycloserine, compared to an inactive substance (placebo), on their ability to reduce fear responses and memory of fear in Veterans with symptoms of Posttraumatic Stress Disorder (PTSD). These responses will be tested using a fear learning and memory task administered by computer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStress Disorders, Posttraumatic
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 8, 2008
Enrollment StartJan 13, 2009
Primary CompletionJun 22, 2015
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 18.2 years ago

Interventions

Hydrocortisonedrug

25 mg/oral one hour prior to extinction task

D-Cycloserinedrug

50 mg/oral one hour prior to extinction task

Placebodrug

One hour prior to extinction task